Pliant Therapeutics, Inc. PLRX

Annual Quarterly

Q4 FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Mar 11, 2026

Pliant Therapeutics, Inc. (PLRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$12.8 million. As of Jun 30, 2026 it held $158.1 million in cash and investments and $28.7 million in total debt.

Revenue
$0
Net income
$-22.37M
+48.3% vs year-ago quarter
Operating cash flow
$-12.80M
+68.5% vs year-ago quarter
Free cash flow
$-12.80M
+68.6% vs year-ago quarter
EPS
$-0.36
+49.3% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
61.92M
+0.9% vs year-ago quarter
Net cash
$129.36M
Q2 FY2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
PLRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1746473

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Operating income
-$23.9M
-$21.8M
-$23.6M
-$28.3M
-$45.6M
Net income
-$22.4M
-$20.0M
-$23.6M
-$26.3M
-$43.3M
Diluted EPS
-$0.36
-$0.32
-$0.38
-$0.43
-$0.71
Operating cash flow
-$12.8M
-$19.2M
-$17.8M
-$21.1M
-$40.6M
Free cash flow
-$12.8M
-$19.2M
-$17.8M
-$21.1M
-$40.7M
Total assets
$189.9M
$202.6M
$225.2M
$276.6M
$299.8M
Total liabilities
$43.0M
$37.4M
$44.0M
$76.3M
$79.7M
Stockholders' equity
$146.9M
$165.2M
$181.2M
$200.3M
$220.1M
Cash and investments
$158.1M
$170.9M
$190.9M
$241.8M
$262.9M
Total debt
$28.7M
$28.8M
$29.1M
$59.9M
$60.4M

Recent SEC filings

Form Description Filed Period
8-K Current report
Results of operations
 Aug 11, 2026 Aug 11, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Officer or director change
 Jul 13, 2026 Jul 9, 2026
8-K Current report
Shareholder vote results
 Jun 11, 2026 Jun 11, 2026
10-Q Quarterly report May 11, 2026 Mar 31, 2026
8-K Current report
Results of operations
 May 11, 2026 May 11, 2026

All 438 Pliant Therapeutics, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.